Targeting the Tie2/Tek receptor in astrocytomas

被引:43
作者
Zadeh, G
Qian, BP
Okhowat, A
Sabha, N
Kontos, CD
Guha, A
机构
[1] Univ Toronto, Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada
[2] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Ctr, Toronto, ON M5G 1X8, Canada
[3] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC USA
基金
加拿大健康研究院;
关键词
D O I
10.1016/S0002-9440(10)63137-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tie2 is an endothelial cell-specific receptor tyrosine kinase, whose activation is positively and negatively modulated by angiopoietin-1 and angiopoietin-2, respectively. Angiopoietin-mediated modulation of Tie2 activation contributes to normal vessel development and stability, however, its role in tumor angiogenesis is not well known. We investigated the role of Tie2 activation in malignant astrocytomas, a common and highly vascularized primary human brain tumor. We found that Tie2 expression and activation increases with increasing malignancy grade of astrocytomas. Inhibition of Tie2, using a kinase-deficient Tie2 construct, decreases growth of malignant human astrocytoma. subcutaneous and intracranial xenografts. Tie2 inactivation disrupted the tumor vascularity, with a decrease in microvascular density, increased presence of abnormally dilated vessels, and loss of interaction between endothelial cells and surrounding smooth muscle cells, all collectively resulting in increased tumor cell apoptosis. Overall, these findings strongly suggest that Tie2 activation contributes significantly to astrocytoma. tumor angiogenesis and growth. We postulate that targeting Tie2 activation, either independently or in conjunction with other anti-angiogenic therapies, such as against vascular endothelial growth factor, is of potential clinical interest.
引用
收藏
页码:467 / 476
页数:10
相关论文
共 53 条
[1]  
Ahmad SA, 2001, CANCER RES, V61, P1255
[2]   Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis - In vivo and in vitro studies [J].
Audero, E ;
Cascone, I ;
Zanon, I ;
Previtali, SC ;
Piva, R ;
Schiffer, D ;
Bussolino, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) :536-541
[3]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[4]   Glomeruloid microvascular proliferation orchestrated by VPF/VEGF - A new world of angiogenesis research [J].
Brat, DJ ;
Van Meir, EG .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (03) :789-796
[5]  
BREIER G, 1992, DEVELOPMENT, V114, P521
[6]  
Burger PC, 1994, TUMORS CENTRAL NERVO
[7]   Direct cell adhesion to the angiopoietins mediated by integrins [J].
Carlson, TR ;
Feng, YZ ;
Maisonpierre, PC ;
Mrksich, M ;
Morla, AO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (28) :26516-26525
[8]   Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system [J].
Carmeliet, P ;
Moons, L ;
Dewerchin, M ;
Mackman, N ;
Luther, T ;
Breier, G ;
Ploplis, V ;
Muller, M ;
Nagy, A ;
Plow, E ;
Gerard, R ;
Edgington, T ;
Risau, W ;
Collen, D .
ATHEROSCLEROSIS IV: RECENT ADVANCES IN ATHEROSCLEROSIS RESEARCH: THE FOURTH SARATOGA INTERNATIONAL CONFERENCE ON ATHEROSCLEROSIS, 1997, 811 :191-206
[9]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[10]   Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].
Davis, S ;
Aldrich, TH ;
Jones, PF ;
Acheson, A ;
Compton, DL ;
Jain, V ;
Ryan, TE ;
Bruno, J ;
Radziejewski, C ;
Maisonpierre, PC ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1161-1169